News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Human Genome Sciences, Inc. Rejects GlaxoSmithKline’s $2.6 Billion Bid, Seeks Higher Offers
April 19, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Human Genome Sciences Inc said it had rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector that has been swept by M&A recently.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
GSK
MORE ON THIS TOPIC
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
·
3 min read
·
Tristan Manalac
Manufacturing
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
May 21, 2026
·
2 min read
·
Nick Paul Taylor
Leadership
Vaxart seeks shareholder support as battle over stock split brews
May 21, 2026
·
2 min read
·
Tristan Manalac
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
